Hille Gieschen

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Christian Zurth, Mikko Koskinen, Robert E. Fricke et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2019 · 102 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal D. Shore, Christian Zurth, Robert E. Fricke et al. · Targeted Oncology · 2019 · 94 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer

Jens Hoffmann, Rolf Bohlmann, N. Heinrich et al. · JNCI Journal of the National Cancer Institute · 2004 · 87 citations

Medicine, Oncology, Pharmacology +17

Higher blood–brain barrier penetration of [¹⁴C]apalutamide and [¹⁴C]enzalutamide compared to [¹⁴C]darolutamide in rats using whole-body autoradiography.

Christian Zurth, Steffen Sandman, Dagmar Trummel et al. · Journal of Clinical Oncology · 2019 · 53 citations

Medicine, Pharmacokinetics, Pharmacology +15

Improving the ex vivo stability of drug ester compounds in rat and dog serum: Inhibition of the specific esterases and implications on their identity

Matthias Koitka, Joachim Höchel, Hille Gieschen et al. · Journal of Pharmaceutical and Biomedical Analysis · 2009 · 47 citations

Medicine, Biochemistry, Pharmacology +14